From: Andrew Johnson
Date: 2009-04-27 10:39:37
#ygrps-yiv-868607840 .ygrps-yiv-868607840hmmessage P { PADDING-RIGHT:0px;PADDING-LEFT:0px;PADDING-BOTTOM:0px;MARGIN:0px;PADDING-TOP:0px;} #ygrps-yiv-868607840 .ygrps-yiv-868607840hmmessage { FONT-SIZE:10pt;FONT-FAMILY:Verdana;} Some people didn’t get to see this – probably because it had some javascript in it. Plenty of red flags here 1st Sanofi, then Baxter International: Thanks to Steve and Michael LM for pointers. Sanofi www.medicalnewstoday… Sanofi Aventis Invests 100 Million Euros In New Facility In Mexico To Produce Seasonaland Pandemic Influenza Vaccine19 Mar 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), announced the signing of an agreement with the Mexican authorities to build a 100 million euro facility to manufacture influenza vaccine in Mexico.The announcement was made during a ceremony attended by Felipe Calderon, President of Mexico, and Nicolas Sarkozy, President of France, who was in Mexico City for a State visit.This facility will be built and operated by sanofi pasteur, the vaccines division of sanofi-aventis Group, which was represented at the ceremony by Chris Viehbacher, Chief Executive Officer of sanofiaventis. “By building this new facility, sanofi-aventis is proud to contribute to the strengthening of Mexico’s health infrastructure and is eager to support Mexico’s exemplary commitment to public health through influenza immunization and pandemic readiness”, said Chris Viehbacher. “This investment illustrates sanofi-aventis’ local approach to global health. This facility will benefit public health in Mexico and the Latin American region, in the context of influenza pandemic preparedness”.The agreement was signed by Birmex’ (Laboratorio de Biológicos y Reactivos de México) and sanofi-aventis’ representatives in the presence of Dr. José Ángel Córdova Villalobos, Minister of Health of Mexico.Under the terms of the agreement, sanofi pasteur will manufacture influenza vaccine in collaboration with Birmex, a Mexican federal vaccine manufacturer. Birmex will perform certain stages of manufacturing and will be responsible for distributing influenza vaccines to the public in Mexico. Sanofi pasteur is planning to start construction of the new vaccine manufacturing facility within a few weeks. Upon completion within four years, the facility will have a yearly capacity of up to 25 million doses of seasonal influenza vaccine.The new influenza vaccine plant will be built in Ocoyoacac, where sanofi-aventis already operates a facility. The plant will be designed to switch to pandemic vaccine manufacturing if a human influenza pandemic is declared and a pandemic influenza strain is identified by the World Health Organization (WHO).As the world leader in research, development and manufacturing of influenza vaccines, sanofi pasteur is working to develop new and improved influenza vaccines to save lives and is actively involved in pandemic preparedness. Over the last five years, sanofi pasteur has been consistently investing in major expansions of its influenza vaccine production capacity in the United States, France, China, and now Mexico. With the production of more than 170 million doses of seasonal influenza vaccine in 2008, sanofi pasteur confirmed its global influenza vaccine market leadership.Seasonal influenza overviewInfluenza is a disease caused by a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes. According to the World Health Organization (WHO), the average global burden of inter-pandemic influenza may be on the order of 1 billion cases per year, leading to 300,000-500,000 deaths worldwide1. In temperate climate zones, seasonal epidemics typically begin in the late Fall and peak in mid-winter, infecting about 5-15% of the population each season, while In tropical zones the virus can be isolated year-round. The disease can affect all age groups, but rates of infections are highest among young children who spread the virus and are a potential source of infection in older age cohorts, whereas rates of serious illness, complications and death are highest in persons aged 65 years and older, as well as in persons with chronic cardiac or respiratory conditions1. The efficacy of vaccination in reducing the burden of the disease, as well as the economic burden of treating influenza, is well established.Pandemic Influenza OverviewInfluenza is a disease caused by a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes1. An influenza pandemic is a global epidemic of an especially virulent virus, newly infectious for humans, and for which there is no preexisting immunity.This is why pandemic strains have such potential to cause severe morbidity and mortality. In an attempt to minimize the impact of a pandemic, many countries are developing national and transnational plans against a possible influenza pandemic situation. For more information on sanofi pasteur and pandemic preparedness, please visit pandemic.influenza.c…About Sanofi AventisSanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).Sanofi pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: www.sanofipasteur.co… or www.sanofipasteur.usReferences:1. www.who.int/vaccine_…Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofiaventis’ annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.Sanofi – Article URL: www.medicalnewstoday… Main News Category: Pharma Industry / Biotech Industry Also Appears In: Immune System / Vaccines, Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions. Save time! Get the latest medical news headlines for your specialist area, in a weekly newsletter e-mail. See www.medicalnewstoday… for details. Send your press releases to pressrelease@medical… —–Original Message—–From: Michael Lawrence Morton [mailto:mlm@archaeoskymatrix…]Sent: 26 April 2009 16:34To: ‘Michael Lawrence Morton’Subject: Baxter International (based in Illinois, USA) admits sending live pandemic flu viruses to subcontractor News Updates from Citizens For Legitimate Government 26 Apr 2009 www.legitgov.org/ All items are here: www.legitgov.org/#br… CLG: Baxter working on vaccine to stop swine flu, though admitted sending live pandemic flu viruses to subcontractor By Lori Price 26 Apr 2009 The OMFG moment of the century. Illinois-based Baxter working on vaccine to ‘stop’ swine flu outbreak in Mexico (25 Apr 2009) But, looky here! Baxter admits sending live avian flu viruses to subcontractor –People familiar with biosecurity rules are dismayed by evidence that human H3N2 and avian H5N1 viruses somehow co-mingled [!] in the Orth-Donau facility. (27 Feb 2009) Is Baxter International taking a page from the Blackwater playbook? Just as Blackwater/Xe keep on killing to justify their multi-billion dollar contracts to provide ‘security’ in Iraq and Afghanistan, Baxter International is poised to make *billions* to vaccinate people against their pandemic. [More at the source.] Briton quarantined as killer flu spreads 26 Apr 2009 A British Airways cabin crew member was taken to hospital with flu-like symptoms yesterday afternoon after falling ill on a flight from Mexico City to Heathrow. The Health Protection Agency said it was keeping a close eye on the situation. New Zealand quarantines 25 amid swine flu alert 26 Apr 2009 Twenty-five students and teachers in New Zealand, some with flu-like symptoms, were quarantined and tested for swine flu after returning from a trip to Mexico, officials said Sunday, as Asia stepped up surveillance for the deadly virus. Minister: 10 NZ students likely have swine flu 26 Apr 2009 New Zealand said Sunday that 10 students “likely” have swine flu after a school trip to Mexico, as governments across Asia began quarantining those with symptoms of the deadly virus and some issued travel warnings for Mexico. New Zealand Health Minister Tony Ryall said none of the patients was seriously ill and they seemed to be recovering. He said they tested positive for influenza but added that there was “no guarantee” the students had swine flu. Mexico Takes Powers to Isolate Cases of Swine Flu –The Centers for Disease Control and Prevention in Atlanta said Saturday that it had sent a team of experts to Mexico to assist with the investigation cover-up of the outbreak.26 Apr 2009 This sprawling capital was on edge Saturday as… President [sic] Felipe Calderón published an order that would give his government emergency powers to address a deadly flu outbreak, including isolating those who have contracted the virus, inspecting the homes of affected people and ordering the cancellation of public events. The newspaper Reforma reported that President Obama, who recently visited Mexico, was escorted around Mexico City’s national anthropology museum on April 16 by Felipe Solis, an archaeologist who died the next day from flu-like symptoms. Those who wish to be added to the list can go here:www.legitgov.org/#su… and add your name. Those who wish to unsubscribe can go here: lists.people-link.ne…. If your email provider has marked this newsletter as spam, please mark it as ‘not spam’ and do not delete from a spam or ‘junk’ folder, as such actions trigger false spam complaints against the CLG. If you have any inquiries/issues with your subscription, please write: signup at legitgov dot org. CLG Managing Editor: Lori Price. Copyright © 2009, Citizens For Legitimate Government ® All rights reserved. —–Original Message—–From: Joanne Joanne [mailto:summersj33@hotmail.c…]Sent: 27 April 2009 09:30To: Andrew JohnsonSubject: RE: Swine Flu -Sanofi and Baxter InternationalJoanne Nothing came through on this mail, can you resend pls. Ta Windows Live Messenger just got better. Find out more!